Compare Amgen, Inc. (AMGN) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs VF Corp — how do they compare? Amgen, Inc. trades at $362.08 (market cap $196.12B), while VF Corp trades at $17.07 (market cap $6.58B). The key difference: Amgen, Inc. is far larger — about 29.8× VF Corp's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | VFC | |
|---|---|---|
Market Cap | $196.12B | $6.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $21.55 |
52-Week Low | $271.18 | $11.66 |
Enterprise Value | $241.41B | $10.73B |
Dividend Yield | 2.77% | 2.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
VFC trades at $16.77, up 1.45% on the day, amid a mixed technical and fundamental backdrop. The stock is bearish on moving averages but shows neutral oscillators, with key support at $16. Recent earnings have been volatile, with a Q1 2026 miss after previous beats, while revenue has declined from $11.8B in 2022 to $9.5B in 2025. The company maintains a solid gross margin of 54.78% but reported a net loss of $189.72M for 2025. Analyst sentiment is mixed with a consensus price target of $20.00.
The outlook for VFC hinges on a successful turnaround, with projected net income turning positive in 2026. Near-term risks include weak consumer confidence and brand-specific challenges at Vans. The current valuation, with a P/S of 0.69, may appeal to value investors if operational improvements continue, but execution risks and high debt levels warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
